Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Update

Health Catalyst, Inc. (NASDAQ:HCAT) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,840,000 shares, an increase of 8.8% from the October 15th total of 2,610,000 shares. Based on an average daily trading volume, of 473,600 shares, the days-to-cover ratio is presently 6.0 days.

Health Catalyst Price Performance

Shares of HCAT stock traded down $0.80 during trading hours on Friday, hitting $7.65. 735,511 shares of the company’s stock were exchanged, compared to its average volume of 548,477. The stock’s 50-day moving average is $8.16 and its 200-day moving average is $7.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market cap of $465.50 million, a price-to-earnings ratio of -5.67 and a beta of 1.32. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.22) EPS. As a group, research analysts forecast that Health Catalyst will post -0.35 EPS for the current year.

Insider Transactions at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the transaction, the chief operating officer now owns 129,690 shares of the company’s stock, valued at $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock worth $257,555 over the last three months. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Health Catalyst

Several large investors have recently made changes to their positions in the business. Quest Partners LLC bought a new position in Health Catalyst in the third quarter valued at about $34,000. Nisa Investment Advisors LLC increased its position in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP increased its position in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC acquired a new stake in Health Catalyst in the third quarter worth about $59,000. Finally, Perfromance Wealth Partners LLC acquired a new stake in Health Catalyst in the second quarter worth about $64,000. Institutional investors own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

HCAT has been the subject of a number of recent research reports. Piper Sandler cut their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Stephens upped their target price on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday. Royal Bank of Canada upped their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Citigroup upped their price target on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $11.71.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.